Inventor · disambiguated record
Glenn Dranoff
Also filed as: DRANOFF GLENN
33 granted patents·38 pending applications·505 citations·filing 1994–2024
97Inventor score
Files withNOVARTIS AG27DANA FARBER CANCER INST INC23DRANOFF GLENN6HARVARD COLLEGE6WHITEHEAD BIOMEDICAL INST2
Top patents by PatentIndex Score
71 records- 0197US10851165B2Antibody molecules to PD-L1 and methods of treating cancerNOVARTIS AG·Filed 2018·Granted Dec 1, 2020·10 cites·80 claims
- 0297US9988452B2Antibody molecules to PD-L1 and uses thereofNOVARTIS AG·Filed 2015·Granted Jun 5, 2018·30 cites·27 claims
- 0397US9821045B2Controlled delivery of TLR3 agonists in structural polymeric devicesHARVARD COLLEGE·Filed 2016·Granted Nov 21, 2017·25 cites·27 claims
- 0497US9370558B2Controlled delivery of TLR agonists in structural polymeric devicesHARVARD COLLEGE·Filed 2013·Granted Jun 21, 2016·32 cites·33 claims
- 0595US10682400B2Combination vaccine devices and methods of killing cancer cellsHARVARD COLLEGE·Filed 2015·Granted Jun 16, 2020·11 cites·26 claims
- 0694US11597934B2Methods and compositions for reducing immunosuppression by tumor cellsDANA FARBER CANCER INST INC·Filed 2020·Granted Mar 7, 2023·3 cites·20 claims
- 0794US5904920ARegulation of systemic immune responses utilizing cytokines and antigensWHITEHEAD BIOMEDICAL INST·Filed 1995·Granted May 18, 1999·123 cites·9 claims
- 0893US10568949B2Method of eliciting an anti-tumor immune response with controlled delivery of TLR agonists in porous polymerlc devicesHARVARD COLLEGE·Filed 2017·Granted Feb 25, 2020·10 cites·27 claims
- 0992US5637483AIrradiated tumor cell vaccine engineered to express GM-CSFWHITEHEAD BIOMEDICAL INST·Filed 1994·Granted Jun 10, 1997·169 cites·17 claims
- 1091US10876120B2Methods and compositions for reducing immunosupression by tumor cellsDANA FARBER CANCER INST INC·Filed 2018·Granted Dec 29, 2020·5 cites·9 claims
- 1191US10258677B2Continuous cell programming devicesHARVARD COLLEGE·Filed 2016·Granted Apr 16, 2019·8 cites·8 claims
- 1288US10328133B2Continuous cell programming devicesMOONEY DAVID J·Filed 2009·Granted Jun 25, 2019·8 cites·8 claims
- 1388US9944931B2Methods and compositions for reducing immunosupression by tumor cellsDANA FARBER CANCER INST INC·Filed 2014·Granted Apr 17, 2018·11 cites·11 claims
- 1488US9402905B2Therapeutic peptidesDANA FARBER CANCER INST INC·Filed 2013·Granted Aug 2, 2016·14 cites·24 claims
- 1586US2024343808A1Antibody molecules to pg-l1 and methods of treating cancer and infectious diseasesNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1684US11851472B2NKG2D-IG fusion protein for cancer immunotherapyDANA FARBER CANCER INST INC·Filed 2020·Granted Dec 26, 2023·1 cites·17 claims
- 1784US11382905B2Immunomodulation by IAP inhibitorsNOVARTIS AG·Filed 2020·Granted Jul 12, 2022·1 cites·4 claims
- 1883US12037583B2Compositions and methods for immunooncologyNOVARTIS AG·Filed 2016·Granted Jul 16, 2024·2 cites·55 claims
- 1982US2025213684A1Combination therapies comprising antibody molecules to tim-3NOVARTIS AG·Filed 2024·Application pending·0 cites
- 2080US12383601B2Chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2020·Granted Aug 12, 2025·1 cites·21 claims
- 2180US10793633B2Therapeutic peptidesDANA FARBER CANCER INST INC·Filed 2016·Granted Oct 6, 2020·2 cites·3 claims
- 2280US10662247B2Compositions and methods of use for augmented immune response and cancer therapyNOVARTIS AG·Filed 2015·Granted May 26, 2020·2 cites·23 claims
- 2380US10106611B2Antibodies that bind to MHC class I polypeptide-related sequence ADANA FARBER CANCER INST INC·Filed 2014·Granted Oct 23, 2018·5 cites·36 claims
- 2479US10786491B2Immunomodulation by IAP inhibitorsNOVARTIS AG·Filed 2017·Granted Sep 29, 2020·1 cites·6 claims
- 2579US7419958B2Method of attenuating reactions to skin irritantsDANA FARBER CANCER INST INC·Filed 2002·Granted Sep 2, 2008·13 cites·15 claims
- 2679US2023383298A1Methods and Compositions for Reducing Immunosupression by Tumor CellsDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 2778US2025092114A1Nkg2d-fc for immunotherapyDANA FARBER CANCER INST INC·Filed 2024·Application pending·0 cites
- 2877US2024190942A1Nkg2d-ig fusion protein for cancer immunotherapyDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 2975US10865233B2NKG2D-fc for immunotherapyDRANOFF GLENN·Filed 2009·Granted Dec 15, 2020·2 cites·14 claims
- 3075US10865232B2NKG2D-IG fusion protein for cancer immunotherapyDANA FARBER CANCER INST INC·Filed 2016·Granted Dec 15, 2020·1 cites·14 claims
- 3174US2022296581A1Immunomodulation by IAP InhibitorsNOVARTIS AG·Filed 2022·Application pending·0 cites
- 3273US2021284737A1Antibody molecules to pd-l1 and uses thereofNOVARTIS AG·Filed 2020·Application pending·0 cites
- 3373US2024139244A1Cells expressing multiple chimeric antigen receptor (car) molecules and uses thereforeNOVARTIS AG·Filed 2023·Application pending·0 cites
- 3471US2024417722A1Compositions and methods for immunooncologyNOVARTIS AG·Filed 2023·Application pending·0 cites
- 3570US2022133889A1Combination therapies comprising antibody molecules to tim-3NOVARTIS AG·Filed 2021·Application pending·0 cites
- 3668US2023039109A1Antibody molecules to cd73 and uses thereofNOVARTIS AG·Filed 2022·Application pending·0 cites
- 3767US2023013364A1Combination therapies comprising antibody molecules to pd-1NOVARTIS AG·Filed 2021·Application pending·0 cites
- 3866US10279021B2Vaccine compositions and methods for restoring NKG2D pathway function against cancersDANA FARBER CANCER INST INC·Filed 2015·Granted May 7, 2019·1 cites·25 claims
- 3965US11998593B2Combination vaccine devices and methods of killing cancer cellsHARVARD COLLEGE·Filed 2020·Granted Jun 4, 2024·0 cites·21 claims
- 4065US2022002382A1Nkg2d-fc for immunotherapyDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 4163US7250291B1Tumor antigens and uses thereofDANA FARBER CANCER INST INC·Filed 1999·Granted Jul 31, 2007·14 cites·5 claims
- 4261US9492518B2Tumor immunityDRANOFF GLENN·Filed 2007·Granted Nov 15, 2016·0 cites·13 claims
- 4360US2008260680A1Method of Attenuating Reactions to Skin IrritantsDANA FARBER CANCER INST INC·Filed 2008·Application pending·0 cites
- 4459US9750729B2Immunomodulation by IAP inhibitorsZAWEL LEIGH·Filed 2009·Granted Sep 5, 2017·0 cites·19 claims
- 4557US2021015860A1Compositions and methods of use for augmented immune response and cancer therapyNOVARTIS AG·Filed 2020·Application pending·0 cites
- 4656US2018207273A1Combination therapies comprising antibody molecules to tim-3DRANOFF GLENN·Filed 2016·Application pending·0 cites
- 4756US2020281973A1Cells expressing multiple chimeric antigen receptor (car) molecules and uses thereforeNOVARTIS AG·Filed 2017·Application pending·0 cites
- 4855US2014286949A1Method of attenuating reactions to skin irritantsDANA FARBER CANCER INST INC·Filed 2013·Application pending·0 cites
- 4953US2025215081A1Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignanciesNOVARTIS AG·Filed 2021·Application pending·0 cites
- 5052US10745483B2Therapeutic peptidesDANA-FARBER CANCER INSTITUTE INC·Filed 2014·Granted Aug 18, 2020·0 cites·6 claims
Showing the top 50 of 71 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Glenn Dranoff files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →